Autogenous vaccines

BioNTech Expands Late-Stage Clinical Oncology Portfolio with Initiation of further Phase 2 Trial with mRNA-based Individualized Neoantigen Specific Immunotherapy in New Cancer Indication

Retrieved on: 
Thursday, October 19, 2023
Survival, BioNTech, Pembrolizumab, Colorectal cancer, American Society of Clinical Oncology, Rated R, Entrepreneurship, Protein, Society, Cancer, Disease, Clinical trial, Neoplasm, Recurrence, Messenger, Roche, BNTX, Safety, Overalls, PDAC, Patient, Autogenous vaccines, Pharmaceutical industry, Genentech, Nature

Neoantigens are proteins that are produced by cancer cells that differ from the proteins produced by healthy cells.

Key Points: 
  • Neoantigens are proteins that are produced by cancer cells that differ from the proteins produced by healthy cells.
  • The trial will be conducted at various sites in the United States, followed by Europe and Asia Pacific region.
  • The recent Phase 1 study has shown that individualized neoantigen vaccination is feasible for this tumor type with low mutational burden and an immunosuppressive microenvironment3.
  • The Phase 2 trial of autogene cevumeran in patients with PDAC is the third later-stage trial based on BioNTech’s individualized cancer vaccine platform iNeST.

Autogenous Vaccines Market is predicted to witness an impressive CAGR of 5.5% over the forecast period (2021-2031)- Persistence Market Research

Retrieved on: 
Thursday, April 8, 2021
Medical specialties, Virology, Medicine, Clinical medicine, Autogenous vaccines, Vaccines, Vaccine, Antibiotic, Mycoplasma, Bacteria

Salmonella, Staphylococcus, Haemophilus, and Mycoplasma are some of the commonly used bacterial strains to develop autogenous bacterial vaccines.

Key Points: 
  • Salmonella, Staphylococcus, Haemophilus, and Mycoplasma are some of the commonly used bacterial strains to develop autogenous bacterial vaccines.
  • According to a revised report published by Persistence Market Research, the autogenous vaccines market was valued over US$ 116 Mn in 2020, and is predicted to witness an impressive CAGR of 5.5% over the forecast period (2021-2031).
  • By type of strain, bacterial autogenous vaccines are expected to contribute to more than 1/3 revenue share in the market.
  • Request for Sample PDF of Report: https://www.persistencemarketresearch.com/samples/29491
    "Increasing preference for autogenous vaccines over antibiotics will catalyze market growth over the coming years," says an analyst of Persistence Market Research.

Autogenous Vaccines Market is predicted to witness an impressive CAGR of 5.5% over the forecast period (2021-2031)- Persistence Market Research

Retrieved on: 
Thursday, April 8, 2021
Medical specialties, Virology, Medicine, Clinical medicine, Autogenous vaccines, Vaccines, Vaccine, Antibiotic, Mycoplasma, Bacteria

Salmonella, Staphylococcus, Haemophilus, and Mycoplasma are some of the commonly used bacterial strains to develop autogenous bacterial vaccines.

Key Points: 
  • Salmonella, Staphylococcus, Haemophilus, and Mycoplasma are some of the commonly used bacterial strains to develop autogenous bacterial vaccines.
  • According to a revised report published by Persistence Market Research, the autogenous vaccines market was valued over US$ 116 Mn in 2020, and is predicted to witness an impressive CAGR of 5.5% over the forecast period (2021-2031).
  • By type of strain, bacterial autogenous vaccines are expected to contribute to more than 1/3 revenue share in the market.
  • Request for Sample PDF of Report: https://www.persistencemarketresearch.com/samples/29491
    "Increasing preference for autogenous vaccines over antibiotics will catalyze market growth over the coming years," says an analyst of Persistence Market Research.

Fish Farming Companies Account for Over 80% Demand of Autogenous Vaccines for Aquaculture: Persistence Market Research

Retrieved on: 
Friday, February 12, 2021
Virology, Vaccines, Autogenous vaccines, Health, Branches of biology, Vaccine, Aquaculture

Autogenous vaccines are widely accepted by aquaculture farming companies during emergency outbreaks, due to very few commercial vaccines being available for specific aquaculture-related diseases.

Key Points: 
  • Autogenous vaccines are widely accepted by aquaculture farming companies during emergency outbreaks, due to very few commercial vaccines being available for specific aquaculture-related diseases.
  • North America and Europe collectively account for nearly one-third share in the global autogenous vaccine for aquaculture market.
  • Fish farming companies are expected to hold a prominent share in the market, owing to high adoption of autogenous vaccine services at these facilities.
  • Get the Sample PDF of the Report: https://www.persistencemarketresearch.com/samples/32293
    "Rise in prevalence of infectious diseases and demand for autogenous vaccines for preventive treatment will boost sales of autogenous vaccines for aquaculture over the coming years," says an analyst at Persistence Market Research.

Fish Farming Companies Account for Over 80% Demand of Autogenous Vaccines for Aquaculture: Persistence Market Research

Retrieved on: 
Friday, February 12, 2021
Virology, Vaccines, Autogenous vaccines, Health, Branches of biology, Vaccine, Aquaculture

Autogenous vaccines are widely accepted by aquaculture farming companies during emergency outbreaks, due to very few commercial vaccines being available for specific aquaculture-related diseases.

Key Points: 
  • Autogenous vaccines are widely accepted by aquaculture farming companies during emergency outbreaks, due to very few commercial vaccines being available for specific aquaculture-related diseases.
  • North America and Europe collectively account for nearly one-third share in the global autogenous vaccine for aquaculture market.
  • Fish farming companies are expected to hold a prominent share in the market, owing to high adoption of autogenous vaccine services at these facilities.
  • Get the Sample PDF of the Report: https://www.persistencemarketresearch.com/samples/32293
    "Rise in prevalence of infectious diseases and demand for autogenous vaccines for preventive treatment will boost sales of autogenous vaccines for aquaculture over the coming years," says an analyst at Persistence Market Research.

Qu Biologics Receives Funding for COVID-19 Prevention/Treatment Research with Qu’s Novel Immunotherapy Platform

Retrieved on: 
Friday, December 18, 2020
Medical specialties, Immunology, Medicine, Immune system, Immune response, Immunity, Adaptive immune system, Infection, Immunopathology, Autogenous vaccines

Unlike traditional vaccines that direct the host adaptive immune response to a very specific antigen, Qus immunotherapy platform engages and trains the innate arm of the immune system that is responsible for providing the bodys first line of defense.

Key Points: 
  • Unlike traditional vaccines that direct the host adaptive immune response to a very specific antigen, Qus immunotherapy platform engages and trains the innate arm of the immune system that is responsible for providing the bodys first line of defense.
  • Optimal innate immune defenses can efficiently contain and clear infection before it spreads and plays an essential role in also directing the adaptive immune response against new infections.
  • Of note, QBKPN treatment was shown to prevent mortality from respiratory infections in aged animals, which typically have reduced innate immune competency.
  • This work will be conducted in collaboration with the NRCs Human Health Therapeutics Research Centre.

Europe $9.87 Bn Preventive Vaccines Market 2020-2026 by COVID-19 Impact, Vaccine Type, Disease, Administration, Patient - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 17, 2020
Health, Pharmaceutical, Medicine, Vaccines, Medical specialties, Vaccination, Virology, COVID-19 vaccine, Medical research, Vaccine, Cancer vaccines, Autogenous vaccines, Vaccine hesitancy

The "Europe Preventive Vaccines Market 2020-2026 by Vaccine Type, Disease, Administration, Patient, and Country: COVID-19 Impact and Growth Opportunity" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Preventive Vaccines Market 2020-2026 by Vaccine Type, Disease, Administration, Patient, and Country: COVID-19 Impact and Growth Opportunity" report has been added to ResearchAndMarkets.com's offering.
  • Europe preventive vaccines market accounted for $9,879.2 million in 2019 and will grow by 10.28% annually over 2020-2026 owing to the rising healthcare expenditure, advancing vaccine technology, and rising need for preventive vaccines especially new COVID-19 vaccines.
  • The balanced (most likely) projection is used to quantify Europe preventive vaccines market in every aspect of the classification from perspectives of Vaccine Type, Disease, Administration, Patient, and Country.
  • Specifically, potential risks associated with investing in Europe preventive vaccines market are assayed quantitatively and qualitatively through a Risk Assessment System.

Asia Pacific Preventive Vaccines Market 2020-2026 by COVID-19 Impact, Vaccine Type, Disease, Administration, Patient, and Growth Opportunity - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 17, 2020
Health, Pharmaceutical, Medical specialties, Medicine, Virology, Vaccination, Vaccines, Clinical medicine, Vaccine, COVID-19 vaccine, Cancer vaccines, Autogenous vaccines

The "Asia Pacific Preventive Vaccines Market 2020-2026 by Vaccine Type, Disease, Administration, Patient, and Country: COVID-19 Impact and Growth Opportunity" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Asia Pacific Preventive Vaccines Market 2020-2026 by Vaccine Type, Disease, Administration, Patient, and Country: COVID-19 Impact and Growth Opportunity" report has been added to ResearchAndMarkets.com's offering.
  • Asia Pacific preventive vaccines market will grow by 12.89% annually with a total addressable market cap of $97.2 billion over 2020-2026 owing to the rising healthcare expenditure, advancing vaccine technology, and rising need for preventive vaccines especially new COVID-19 vaccines.
  • The balanced (most likely) projection is used to quantify Asia Pacific preventive vaccines market in every aspect of the classification from perspectives of Vaccine Type, Disease, Administration, Patient, and Country.
  • Specifically, potential risks associated with investing in Asia Pacific preventive vaccines market are assayed quantitatively and qualitatively through a Risk Assessment System.

North America Preventive Vaccines Market 2020-2026 by COVID-19 Impact, Vaccine Type, Disease, Administration, & Patient - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 17, 2020
Health, Pharmaceutical, Medical specialties, Medicine, Virology, Vaccination, Vaccines, Health sciences, COVID-19 vaccine, Medical research, Vaccine, Cancer vaccines, Autogenous vaccines, Vaccine hesitancy

The "North America Preventive Vaccines Market 2020-2026 by Vaccine Type, Disease, Administration, Patient, and Country: COVID-19 Impact and Growth Opportunity" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "North America Preventive Vaccines Market 2020-2026 by Vaccine Type, Disease, Administration, Patient, and Country: COVID-19 Impact and Growth Opportunity" report has been added to ResearchAndMarkets.com's offering.
  • North America preventive vaccines market is expected to grow by 9.98% annually in the forecast period and reach $30.01 billion by 2026 driven by increasing healthcare expenditure, advancing vaccine technology, and rising need for preventive vaccines especially new COVID-19 vaccines.
  • The balanced (most likely) projection is used to quantify North America preventive vaccines market in every aspect of the classification from perspectives of Vaccine Type, Disease, Administration, Patient, and Country.
  • Specifically, potential risks associated with investing in North America preventive vaccines market are assayed quantitatively and qualitatively through a Risk Assessment System.

Emergex Vaccines Raises US$11 million to Advance Pipeline of Synthetic T-Cell Vaccines for Infectious Diseases

Retrieved on: 
Wednesday, November 18, 2020
Medical specialties, Immunology, Medicine, Clinical medicine, Vaccine, T cell, Immunity, Antibody, Autoimmunity, Vaccine hesitancy, Autogenous vaccines

This round follows a successful $11 million Series A completed in January 2020.

Key Points: 
  • This round follows a successful $11 million Series A completed in January 2020.
  • Emergexs next generation vaccines have been designed to expand the bodys natural immune response by programing CD8+ T-cells to rapidly recognise and respond to pathogens.
  • This approach is aimed at providing effective prevention of disease while eliminating the allergic, autoimmune or antibody mediated side effects associated with traditional vaccines.
  • Emergexs vaccines are 100% synthetic - requiring no biology for manufacturing - thus having the potential to be rapidly produced and cost-effectively scaled.